MeSH | Pneumococcal Infections (D011008)

Pneumococcal Infections D011008

Diseases [C] » Infections [C01] » Bacterial Infections and Mycoses » Bacterial Infections » Gram-Positive Bacterial Infections » Streptococcal Infections » Pneumococcal Infections

Description

Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE. MeSH

Hierarchy View

View MeSH Tree

Subtype Terms (2)

Meningitis, Pneumococcal
2 approved drugs

Pneumonia, Pneumococcal
21 drugs (11 approved, 10 experimental)

Approved Indicated Drugs (3)

lincomycin (lincocin)

phenoxymethylpenicillin

serotype-specific whole-cell pneumococcal vaccines

Phase 4 Indicated Drugs (17)

10-valent Pneumococcal Conjugate Vaccine (Pneumosil)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23)

diphtheria toxoid

inactivated influenza vaccine

levofloxacin (levaquin)

Monovalent group C meningococcal vaccine (Menomune-C)

multi-valent pneumococcal conjugate vaccine

neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine

pneumococcal 13-valent conjugate vaccine (prevnar 13)

pneumococcal 7-valent conjugate vaccine (Prevnar)

quadrivalent groups a, c, y, and w-135 meningococcal vaccine (Menomune-A/C/Y/W-135)

Phase 3 Indicated Drugs (18)

15-valent pneumococcal conjugate vaccine (VAXNEUVANCE)

20-valent pneumococcal conjugate vaccine (Prevnar 20)

bivalent oral polio vaccine (bopv), type 1 and type 3 (BOPV)

bnt162b2 (Comirnaty)

Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine (Kinrix)

diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine (Pediarix)

haemophilus influenzae type b conjugate vaccine (HibTITER)

hepatitis a vaccine, inactivated (vaqta)

hepatitis b vaccine (recombinant) (Recombivax)

human rotavirus, live attenuated (Rotarix)

inactivated poliovirus type 2 vaccine

live attenuated varicella vaccine (Varivax)

measles, mumps, and rubella vaccine (MMR)

meningococcal conjugate vaccine (Menveo)

Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi)

mrna-1273 (Spikevax)

rotavirus vaccine, live, oral, pentavalent (Rotateq)

Phase 2 Indicated Drugs (8)

acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia)

aluminum hydroxide (Gaviscon)

nintedanib (ofev)

pirfenidone (esbriet)

sp0202-vii pneumococcal conjugate vaccine

Phase 1 Indicated Drugs (10)

9 valent pneumococcal conjugate vaccine

Tetanus and diphtheria toxoids adsorbed (Decavac)

Organization Involved with Phase 4 Indications (32)

Agence de Médecine Préventive, France

Belarusian State Medical University

Bill and Melinda Gates Foundation

Chengdu Institute of Biological Products Co.,Ltd.

China National Biotec Group Co., Ltd

Department of Health, United Kingdom

Department of Veteran Affairs

Friedrich Schiller University

Government of China

Government of Taiwan

Health Protection Agency, United Kingdom

Institute of Sera and Vaccines RAS, Moscow

Korea University

Minsk State Clinical Hospital No 9

Moorgreen Hospital, Southampton

National Institutes of Health (NIH)

National Taiwan University

Public Health England

Royal Liverpool & Broadgreen University Hospitals NHS Truts

Russian Academy of Medical Sciences

University of Bristol

University of Indonesia

University of Liverpool

University of London

University of Malawi

University of Oxford

Organization Involved with Phase 3 Indications (24)

Canadian Immunization Research Network

Canadian Institutes of Health Research (CIHR)

Dalhousie University

GlaxoSmithKline

Government of Finland

Government of Italy

Government of Netherlands

Mason Medical Research Trust

Menzies School of Health Research

National Health and Medical Research Council, Australia

Netherlands Vaccine Institute

People's Liberation Army of China

Seoul National University

Sinovac Biotech Co., Ltd

University of British Columbia

University of Calgary

University of Melbourne

University of Montreal

University of Siena

University of Sydney

Utrecht University

Walvax Biotechnology Co., Ltd.

Organization Involved with Phase 2 Indications (13)

CIHR Canadian HIV Trials Network

Genocea Biosciences, Inc.

Medical Research Council, The Gambia

National Institute of Allergy and Infectious Diseases (NIAID)

University of Colorado, Denver

University of Lyon

University of Paris

University of Western Ontario

Organization Involved with Phase 1 Indications (17)

Alaska Native Tribal Health Consortium

Centers for Disease Control and Prevention (CDC)

Emory University

ImmunoBiology Ltd

National Institute on Aging (NIA)

ORION Clinical Services

Oxford Therapeutics Consulting Limited

Southcentral Foundation

Stony Brook University

Tianjin Cansino Biotechnology Inc

University of Limoges

University of Maryland

University of Toledo

Organization Involved with Other Experimental Indications (3)

Institut National de la Santé Et de la Recherche Médicale, France

King Saud University

University of Colorado

Hierarchy Tree View

MeSH

UMLS Data

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.